Skip to main content

Table 2 Univariable analysis of risk factors for total VTE of 29 patients

From: Venous thromboembolism in hospitalized patients receiving chemotherapy for malignancies at Japanese community hospital: prospective observational study

Variable No. of patients (%) OR (95% CI) P
Sex and age (yr.)
  < 70 17 /64 27 1.0 (ref.)  
  ≥ 70 male 4 /19 21 0.7 (0.2–2.5) 0.77
  ≥ 70 female 8 /14 57 3.7 (1.1–12.2)a 0.054
BMI
  < 25 21 /74 28 1.0 (ref.)  
  ≥ 25 8 /23 35 1.4 (0.5–3.6) 0.75
Reduced mobilityb
 No 22 /87 25 1.0 (ref.)  
 Yes 7 /10 70 6.9 (1.6–29.0)a 0.007*
Previous chemotherapy
 No 24 /78 31 1.0 (ref.)  
 Yes 5 /19 26 0.8 (0.3–2.5) 0.92
Time from tumor onset (mo.)
  < 6 or >12 23 /85 27 1.0 (ref.)  
 6–12 6 /12 50 2.7 (0.8–9.2) 0.17
Central venous access device
 No 1 / 7 14 1.0 (ref.)  
 Yes 28 /90 31 2.7 (0.3–23.6) 0.67
Using anti-VEGF antibody
 No 26 /80 33 1.0 (ref.)  
 Yes 3 /17 18 0.5 (0.1–1.7) 0.26
Distant metastases
 No 7 /32 22 1.0 (ref.)  
 Yes 22 /65 34 1.8 (0.7–4.9) 0.33
Developing acute infectionc
 No 18 /67 27 1.0 (ref.)  
 Yes 11 /30 37 1.6 (0.6–3.9) 0.46
Platelet count (/μL)d
  < 350,000 25 /87 29 1.0 (ref.)  
  ≥ 350,000 4 /10 40 1.7 (0.4–6.4) 0.48
Hemoglobin (g/dL)d
  ≥ 10 26 /84 31 1.0 (ref.)  
  < 10 3 /13 23 0.7 (0.2–2.6) 0.75
Leukocyte count (/μL)d
  < 11,000 29 /93 31 1.0 (ref.)  
  ≥ 11,000 0 / 4 0 0.2 (0.0–4.7) 0.31
D-dimer (μg/mL)de
  < 1.5 7 /36 19 1.0 (ref.)  
  ≥ 1.5 19 /58 33 2.0 (0.8–5.4) 0.24
TAT (ng/mL)de
  < 2.1 10 /50 20 1.0 (ref.)  
  ≥ 2.1 16 /44 36 2.3 (0.9–5.8) 0.12
PIC (μg/mL)d, e
  ≥ 1.8 7 /21 33 1.0 (ref.)  
  < 1.8 19 /73 26 0.7 (0.2–2.0) 0.70
TAT ≥2.1 ng/mL and PIC <1.8 μg/mLd, e
 No 14 /65 22 1.0 (ref.)  
 Yes 12 /29 41 2.6 (1.0–6.6) 0.082
  1. VTE venous thromboembolism, OR odds ratio, CI confidence interval, BMI body mass index, VEGF vascular endothelial cell growth factor, TAT thrombin-antithrombin complex, PIC plasmin α2-plasmin inhibitor complex
  2. * P < 0.05. a95% CI over 1.0. bBedrest with bathroom privileges for at least three days at baseline, either due to patient’s limitation or on physician’s order. cDuring the three-month observation period. dMeasured at baseline, just before the first cycle of chemotherapy. eUnmeasured in three patients